OriGene Technologies Launches 5,000 Human Antigen Standards For Antibody Validation
Rockville, MD - OriGene Technologies, Inc. announces it has launched a new product line for antibody validation - VERIFY™ Antigen Standard - a collection of tagged over-expression cell lysates to be used as Western blot standards. The offering covers 5,000 over-expressed human proteins, each with a built-in C-terminal Myc/DDK tag for easy expression verification and antibody validation.
Antibody and antibody-based assays are important biomedical research tools. Monoclonal antibody based drugs have already been accepted clinically as breakthrough new generation therapeutics. However researchers in this field are still faced with several critical challenges. Many antibodies in the market are poorly characterized for specificity and affinity. Lack of quality antigen standards also makes it difficult and time consuming to validate the quality of commercial antibodies from different providers. The availability of these initial 5000 VERIFY™ Antigen Standards will not only provide scientists with easy access to a validated antigen of interest, they can also be easily quantified with Myc/DDK tag standard hence providing definitive detection sensitivity of a particular antibody.
Built on its strength as the leading full-length cDNA clone provider and extensive TrueORF clone collection, OriGene has developed comprehensive, protein specific over-expression cell lysates for antibody validation. The first 5,000 offerings are primarily for Western blot standards. "We believe VERIFY™ Antigen Standards represent a significant milestone for the antibody market," said Wei-Wu He, Ph.D, Chief Executive Officer of OriGene. "We are proud to take a leadership position in this market, and extremely excited about its commercial opportunities. We will provide these products to our biomedical research customers as well as antibody developers. We believe all antibodies in the future will be fully validated with our suite of antigen standards, and all commercial antibodies will be complemented with an antigen control for each application. The TrueORF cDNA clones will enable OriGene to develop antigen standards covering the entire human genome eventually."
About OriGene
Based in Rockville, Maryland, OriGene Technologies, Inc. pioneered the development of patented processes for the isolation of full-length cDNA, and commercialized an extensive gene bank of authentic full-length cDNA clones. In addition to cDNA clones, OriGene offers unique gene expression products such as TissueScan cancer qPCR arrays for biomarker discovery and validation. OriGene is committed to its mission to be "Your Gene Company", in supplying everything a researcher would need for gene based research.
SOURCE: OriGene Technologies, Inc.